Trivalent rHA Dose Escalation Study in Elderly Subjects

Summary

This study will compare the safety and immunogenicity of three different dose levels of an experimental recombinant influenza HA protein vaccine to a standard inactivated influenza vaccine in heallthy elderly subjects ages 65-80. Blood and nasal secretions for assessment of antibody responses will be obtained from all subjects prior to and one month after vaccination.

Timeline

Start

—

Primary completion

—

Completion

2004-06

Drugs

Indications